ArticlePloS one2019
Mutation and immune profiling of metaplastic breast cancer: Correlation with survival.
Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05660083 (Phase II Trial of Alpelisib With iNOS Inhibitor and Nab-paclitaxel in Patients With HER2 Negative Metastatic or Locally Advanced Metaplastic Breast Cancer), which is not on this map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Trial of Alpelisib With iNOS Inhibitor and Nab-paclitaxel in Patients With HER2 Negative Metastatic or Locally Advanced Metaplastic Breast Cancer (MpBC)
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- The Correlation Between PD-L1 Expression in Metaplastic Breast Cancer and Clinical-Pathological Features and Prognosis.Medicina (Kaunas, Lithuania) · 2026Article
- Activation of PI3K and deletion of p53 in keratin 15-expressing mouse mammary cells induces tumor heterogeneity and plasticity modeling metaplastic breast cancer.The Journal of pathology · 2025Article
- Metaplastic carcinoma of breast with heterologous mesenchymal differentiation (carcinosarcoma) having an endothelial component: a case report.Journal of medical case reports · 2025Article
- A dramatic response to an immune checkpoint inhibitor plus chemotherapy in a patient with metastatic metaplastic carcinoma of the breast: A case report.Thoracic cancer · 2024Article
- Translational Aspects in Metaplastic Breast Carcinoma.Cancers · 2024Review
- Article
- The conundrum of metaplastic breast cancer: a single Egyptian institution retrospective 10-year experience (2011-2020).Journal of the Egyptian National Cancer Institute · 2023Article
- Article
- Metaplastic Carcinoma of the Axillary Breast With Heterologous Mesenchymal (Chondroid) Differentiation: A Difficult Case and Literature Review.Breast cancer : basic and clinical research · 2023Article
- Article
- Metaplastic Breast Cancer: Mesenchymal Subtype Has Worse Survival Outcomes.Breast care (Basel, Switzerland) · 2022Article
- Genomic Markers of CDK 4/6 Inhibitor Resistance in Hormone Receptor Positive Metastatic Breast Cancer.Cancers · 2022Article
- Article
- Differences of Clinicopathological Features between Metaplastic Breast Carcinoma and Nonspecific Invasive Breast Carcinoma and Prognostic Profile of Metaplastic Breast Carcinoma.The breast journal · 2022Review
- Epithelial Mesenchymal Transition and Immune Response in Metaplastic Breast Carcinoma.International journal of molecular sciences · 2021Review
- Tumor-infiltrating lymphocyte abundance and programmed death-ligand 1 expression in metaplastic breast carcinoma: implications for distinct immune microenvironments in different metaplastic components.Virchows Archiv : an international journal of pathology · 2021Article
- A Case Series of Metastatic Metaplastic Breast Carcinoma Treated With Anti-PD-1 Therapy.Frontiers in oncology · 2021Article
- An Update on the Molecular Pathology of Metaplastic Breast Cancer.Breast cancer (Dove Medical Press) · 2021Review
- Any Role of PIK3CA and PTEN Biomarkers in the Prognosis in Oral Squamous Cell Carcinoma?Life (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
The goal of this study is to characterize the genomic and immune profiles of metaplastic breast cancer (MpBC) and identify the association with survival through an analysis of archived tumor tissue. A next-generation sequencing-based mutational assay (Onco-48) was performed for 21 MpBC patients. Clinicopathologic characteristics were captured, including relapse free survival (RFS) and overall survival (OS). Immunohistochemistry (IHC) for CD3, CD4, CD8, and programmed death-ligand 1 (PD-L1) was also performed. Recurrence free survival (RFS) at 5 years was 57% (95% CI 0.34-0.75) and overall survival (OS) at 5 years was 66% (95% CI 0.41-0.82). The most commonly altered genes were TP53 (68.4%, 13/19), PIK3CA (42.1%, 8/19), and PTEN (15.8%, 3/19. For patients with PIK3CA mutations, RFS and OS were significantly worse than for those without (HR 5.6, 95% CI 1.33-23.1 and HR 8.0, 95% CI 1.53-41.7, respectively). Cox regression estimated that PD-L1 expression was associated with worse RFS and OS (HR 1.08, 95% CI 1.01-1.16 and HR 1.05, 95% CI 1.00-1.11, respectively, for an absolute increase in PD-L1 expression of 1%). In conclusion, PIK3CA mutation and PD-L1 expression confer poor prognosis in this cohort of patients with MpBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.